If they thought he was crazy, they never told him so. Still, everybody from friends and family to Wall Street won-dered why Thomas P. MacMahon would agree to leave a nice executive job at Hoffman-La Roche, a division of Swiss phar-maceutical giant Roche, to take the top position at Laboratory Corp. of America in 1997. LabCorp was then a cranky, ill-functioning two-year-old, formed out of a merger of two clinical labs, one cast off by Roche and one by billionaire Ronald Perelman. Within months of the merger a phalanx of managers quit. Sales slipped. So did the operating margin. LabCorp lost $8 million on sales of $813 million in the first half of 1996. It was $1 billion in debt.
展开▼
机译：如果他们认为他疯了，他们就永远不会告诉他。尽管如此，从朋友，家人到华尔街的每个人都想知道为什么Thomas P. MacMahon同意在瑞士制药巨头罗氏（Roche）的子公司霍夫曼-拉罗氏（Hoffman-La Roche）留下出色的行政工作，以在实验室公司（Laboratory Corp.）担任最高职位LabCorp当时是个老旧，功能失调的两岁男孩，由两个临床实验室合并而成，一个由罗氏（Roche）淘汰，另一个由亿万富翁罗纳德·佩雷尔曼（Ronald Perelman）合并而成。合并后的几个月内，一批管理人员退出了。销售下滑。营业利润率也是如此。 LabCorp在1996年上半年的销售额为8.13亿美元，亏损了800万美元。债务为10亿美元。
展开▼
